Clinical Trial Detail

NCT ID NCT02312102
Title Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

acute myeloid leukemia

bone marrow cancer

Therapies

Bortezomib + Lenalidomide

Age Groups: adult

No variant requirements are available.